

Date and time: Tuesday 2 September 2014, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting **Diagnosis and monitoring of asthma**
12

Place: **Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ**

Present:

- Tara Burn, Patient member
- Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric Respiratory Medicine
- Ren Gilmartin, Respiratory Nurse Specialist
- Val Hudson, Patient member
- Angela Key, Chief Respiratory Physiologist
- Matthew Masoli, Consultant Respiratory Physician
- Melanie McFeeters, Consultant Nurse in Children’s Respiratory Diseases
- Andrew Menzies-Gow (Chair), Consultant in Respiratory Medicine
- Tahmina Siddiqui, General Practitioner partner
- Michael Thomas, Professor of Primary Care Research & Principal in General Practice (MT did not formally participate for the discussion on FeNO in items 3, 4 or 7)
- Louise Craig, Research Fellow, NETSCC (item 6 only)
- Alex Haines, Health Economist, NCGC
- Bernard Higgins, Clinical Director, NCGC
- Emma Madden, Research Fellow, NCGC
- Jill Parnham, Operations Director, NCGC (item 6 only)
- Amelia Unsworth, Project Manager, NCGC
- Giulia Zuodar, Document Editor/Process Assistant, NCGC (notes)

Apologies:

- John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
- Emily Davies, Senior Research Fellow, NCGC
- Elisabetta Fenu, Senior Health Economist, NCGC
- Caroline Keir, Guidelines Commissioning Manager, NICE
- Georgina Russell, RCP Clinical Fellow (Specialist Trainee Adviser)

In attendance:

NICE Staff: NICE attendee 1	Gareth Haman, Senior Medical Editor	
--------------------------------	--	--

Observers:

None		
------	--	--

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the twelfth meeting of this GDG. Apologies were received from JA, CK, ED and GR.

The Chair reviewed and requested updates to the declarations of interest register.

AMG declared 'Filming for Boehringer Ingelheim on the use of Tiotropium in severe asthma.' This was classified as a non-specific personal pecuniary interest. The guideline lead agreed that no further action was required.

No other new declarations of interest were received and therefore no further action was required.

2. **GDG11 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Review draft recommendations/LETRs**

The GDG reviewed and made edits to the draft 'recommendations and link to evidence' for lung function tests for monitoring and FeNO for monitoring. MT did not formally participate for the discussion on FeNO but was present to answer questions at the request of the Chair.

4. **Re-runs: Evidence review: FeNO for diagnosis**

The GDG reviewed the evidence on the clinical and cost effectiveness of FeNO for diagnosis. MT did not formally participate for the discussion on FeNO but was present to answer questions at the request of the Chair.

5. **Re-runs: Evidence review: History of atopic disorders**

The GDG reviewed the evidence on the clinical and cost effectiveness of history of atopic disorders.

6. **Future research recommendations**

The GDG reviewed the draft future research recommendations.

7. **Diagnostic algorithms & draft recommendations**

The GDG reviewed the draft diagnostic algorithms and draft recommendations. MT did not formally participate in the discussion relating to FeNO but was present to answer questions at the request of the Chair.

8. **Any other business**

None.

Date, time and venue of the next meeting

Tuesday 7 October 2014, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ.